Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesLong-Term Debt RepaymentsNet Cash FlowNet IncomeShare-based CompensationShares IssuedShort-Term Debt issuances
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Serina Therapeutics (SER) Short-Term Debt issuances (2021 - 2024)

Serina Therapeutics (SER) has disclosed Short-Term Debt issuances for 4 consecutive years, with $110000.0 as the latest value for Q4 2024.

  • Quarterly Short-Term Debt issuances changed N/A to $110000.0 in Q4 2024 from the year-ago period, while the trailing twelve-month figure was $110000.0 through Sep 2025, down 96.25% year-over-year, with the annual reading at $3.0 million for FY2024, N/A changed from the prior year.
  • Short-Term Debt issuances hit $110000.0 in Q4 2024 for Serina Therapeutics, up from $8000.0 in the prior quarter.
  • In the past five years, Short-Term Debt issuances ranged from a high of $11.5 million in Q1 2023 to a low of -$13.5 million in Q3 2023.
  • Historically, Short-Term Debt issuances has averaged $964846.2 across 4 years, with a median of $1.5 million in 2021.
  • Biggest YoY gain for Short-Term Debt issuances was 666.67% in 2023; the steepest drop was 1450.0% in 2023.
  • Year by year, Short-Term Debt issuances stood at $1.5 million in 2021, then changed by 0.0% to $1.5 million in 2022, then tumbled by 1000.0% to -$13.5 million in 2023, then skyrocketed by 100.81% to $110000.0 in 2024.
  • Business Quant data shows Short-Term Debt issuances for SER at $110000.0 in Q4 2024, $8000.0 in Q3 2024, and $525000.0 in Q2 2024.